Literature DB >> 9589775

Substrate utilization/insulin resistance in sepsis/trauma.

R R Wolfe1.   

Abstract

Endogenous substrate metabolism is markedly altered in critically ill patients. Glucose production is elevated not only in the post-absorptive state, but the normal suppressive effect of exogenous glucose and glucose production is greatly diminished. In the post-absorptive state, glucose clearance is generally elevated, potentially causing hypoglycaemia in extreme cases. Somewhat paradoxically, the ability of insulin to stimulate glucose uptake is diminished, so that hyperglycaemia is often evident during nutritional intake. Lipolysis, the breakdown of peripheral fat, is accelerated, meaning that free fatty acids are released into plasma at a rate far exceeding their oxidation. Some of the excess fatty acids are re-esterified in the liver, leading to accelerated hepatic triglyceride formation. A large increase in hepatic triglyceride stores can ensue if the rate of excretion of triglycerides in very low density lipoproteins is not accelerated commensurately with the increased triglyceride production. Indirect calorimetry measurements support the notion that the large increase in availability of fatty acids may lead to a greater reliance on fatty acids as energy substrates. Nonetheless, carbohydrates should be the predominant source of non-protein calories, because the accompanying insulin response effectively enhances protein synthesis. There is already ample fat available via endogenous lipolysis, and more fat given exogenously provides little further benefit.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9589775     DOI: 10.1016/s0950-351x(97)80926-3

Source DB:  PubMed          Journal:  Baillieres Clin Endocrinol Metab        ISSN: 0950-351X


  14 in total

Review 1.  Blood glucose management during critical illness.

Authors:  Barry A Mizock
Journal:  Rev Endocr Metab Disord       Date:  2003-05       Impact factor: 6.514

2.  Hyperglycemia and oxidative stress: complex relationships with attractive prospects.

Authors:  Xavier Leverve
Journal:  Intensive Care Med       Date:  2003-04       Impact factor: 17.440

3.  FGF21 is increased by inflammatory stimuli and protects leptin-deficient ob/ob mice from the toxicity of sepsis.

Authors:  Kenneth R Feingold; Carl Grunfeld; Josef G Heuer; Akanksha Gupta; Martin Cramer; Tonghai Zhang; Judy K Shigenaga; Sophie M Patzek; Zoe W Chan; Arthur Moser; Holly Bina; Alexei Kharitonenkov
Journal:  Endocrinology       Date:  2012-04-02       Impact factor: 4.736

Review 4.  Nonthyroidal illness syndrome in children.

Authors:  Seth D Marks
Journal:  Endocrine       Date:  2009-09-25       Impact factor: 3.633

5.  Influence of acute hyperglycemia in human sepsis on inflammatory cytokine and counterregulatory hormone concentrations.

Authors:  Wen-Kui Yu; Wei-Qin Li; Ning Li; Jie-Shou Li
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

6.  Muscle protein synthesis and balance responsiveness to essential amino acids ingestion in the presence of elevated plasma free fatty acid concentrations.

Authors:  Christos S Katsanos; Asle Aarsland; Melanie G Cree; Robert R Wolfe
Journal:  J Clin Endocrinol Metab       Date:  2009-05-19       Impact factor: 5.958

7.  Responses of adipose and muscle lipoprotein lipase to chronic infection and subsequent acute lipopolysaccharide challenge.

Authors:  Frédéric Picard; Denis Arsenijevic; Denis Richard; Yves Deshaies
Journal:  Clin Diagn Lab Immunol       Date:  2002-07

Review 8.  Stress-hyperglycemia, insulin and immunomodulation in sepsis.

Authors:  Paul E Marik; Murugan Raghavan
Journal:  Intensive Care Med       Date:  2004-02-26       Impact factor: 17.440

9.  The acute phase protein Serum Amyloid A induces lipolysis and inflammation in human adipocytes through distinct pathways.

Authors:  Aurélie Faty; Pascal Ferré; Stéphane Commans
Journal:  PLoS One       Date:  2012-04-19       Impact factor: 3.240

Review 10.  Nutrition in the intensive care unit.

Authors:  C Weissman
Journal:  Crit Care       Date:  1999-09-17       Impact factor: 9.097

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.